Gan & Lee Pharmaceuticals
甘李药业
Gan & Lee Pharmaceuticals is a Chinese biopharmaceutical company best known as Qiming Venture Partners' first healthcare investment and one of its most consequential. In 2010, when the company had hit three consecutive years of flat revenue, Qiming managing partner Nisa Leung overrode internal opposition to back it as the largest investor, betting on the market potential of third-generation insulin and the company's underlying strength . The decade-long holding became a "super deal" generating returns exceeding RMB 10 billion .
elsewhere's corpus does not otherwise cover this subject directly — the retrieved materials concern Qiming's investment history rather than Gan & Lee's own operations, pipeline, or corporate profile.
AI-generated — may contain errors, please verify.
Coverage
What Would Qiming Venture Partners Look Like Without Nisa Leung?
Together, we welcome a new era.
The Trillion-Yuan Blueprint for Peptide Drugs: From Diabetes Medication to Weight-Loss Wonder | BlueRun Ventures Biotech Forum Recap
From Pharmaceuticals to Consumer Goods: A Wave of Value Creation
Qiming Venture Partners Raises Record 6.5 Billion RMB; Duane Kuang: Scale Was Not the Goal
2020 was a watershed year.
